Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04684589 · ClinicalTrials.gov registry record · Phase 2
Effect of PDE5 Inhibition on Adipose Metabolism in Humans
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT04684589: Completed Phase 2 study, sponsored by Vanderbilt University Medical Center.
NCT04684589 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 89 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04684589, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
This is a randomized, double-blinded, placebo-controlled study of the effects of PDE5 inhibition with tadalafil on adipose tissue in obese individuals. Adipose metabolism will be measured using magnetic resonance imaging (MRI) scans and by aspirating a small amount of adipose to measure gene expression.
Primary Outcome
Measured by fat signal fraction (FSF) at Week 12. FSF is the percent of MRI signal derived from lipids within a voxel. Lower FSF values indicate greater lipid consumption and correspond to brown adipose tissue (BAT), whereas higher FSF values indicate lipid storage and correspond to white adipose tissue (WAT).
Interventions
- DRUG Placebo
- DRUG Tadalafil 20 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2021-03-16 |
| Est. Completion | 2025-06-24 |
| Phase | Phase 2 |
What the finished NCT04684589 record still lists
NCT04684589 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04684589 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04684589 about?
NCT04684589 is a clinical study titled "Effect of PDE5 Inhibition on Adipose Metabolism in Humans". This is a randomized, double-blinded, placebo-controlled study of the effects of PDE5 inhibition with tadalafil on adipose tissue in obese individuals. Adipose metabolism will be measured using magnetic resonance imaging (MRI) scans and by aspirating a small amount of adipose to measure gene express...
What is the current status of trial NCT04684589?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2021-03-16. Estimated completion is 2025-06-24.
What interventions are being tested in trial NCT04684589?
The interventions under investigation include: Placebo (DRUG), Tadalafil 20 MG (DRUG).
Who is sponsoring clinical trial NCT04684589?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04684589's enrollment target sits among peer trials
89 802nd of 2000 higher than 1,198 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI